Both our Aptiva instruments are placed in Switzerland, thanks to our long term partner Ruwag. The second Aptiva instrument, similar to the first unit has been installed in an important hospital in Switzerland. With the latest PMAT technology and the new Biomarkers developed, we will help our customers to close the seronegative gap.
The EEMEA team is proud to be in the limited release of the new Aptiva which is planned for the final release by the end of 2022.
Since EEMEA team never stops, we have several installations of Aptiva coming up in the next months. Stay tuned!!
Andrea De Cristofaro, Application Specialist Autoimmunity